Non-small Cell Lung Cancer
Conditions
Keywords
Lung Cancer, Biomarkers, Bone, Metastases
Brief summary
CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies
Interventions
BIOLOGICALSerum and plasma samples
Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer * age over 18 years * patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years * patient who signed the informed consent by the study protocol
Exclusion criteria
were: * any ongoing treatment for cancer * any history of cancer within 5 years before the diagnosis of lung cancer * any psychological, sociological or geographical conditions that would not allow the study follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Serum levels of osteoprotegerin | At the time of initial surgery | The serum levels of osteoprotegerin, as assessed by standard ELISA methods, will be measured to to evaluate at the time of initial surgery, the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. |
Countries
France
Contacts
Primary ContactNicolas Girard
Backup ContactCyrille Confavreux
Outcome results
None listed